Two hair supplements for men with androgenic alopecia
Official title: Clinical Efficacy and Safety of Two Food Supplements on Hair Health in Caucasian Male Subjects With Androgenic Alopecia : a Multicentric, Randomised, Double-blind, Placebo-controlled Clinical Study
Run by Activ'inside · NCT07806474 · Data updated 2026-11-12
This study tests two daily hair supplement formulations against placebo to see if they improve hair growth and perceived hair quality in men with mild to moderate androgenetic alopecia over 84 days.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 35 Years to 65 Years |
| Sex | Men only |
| Enrollment | 99 (estimated) |
| Sponsor | Activ'inside Industry-sponsored |
| Locations | 6 sites (Rende, Cosenza and 5 other locations) |
| Status | Recruiting |
| Started | October 5, 2026 |
| Main results expected | March 5, 2027 |
| Study ends | March 5, 2027 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT07806474 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy Caucasian men aged 35–65 with mild to moderate androgenetic alopecia (Hamilton-Norwood II–III) and 5–7 cm of hair length.
✕Probably not a fit
Some participants may not experience noticeable hair improvement despite taking the supplements.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial compares two active formulations containing plant extracts and selenium-enriched yeast with a placebo in healthy Caucasian men aged 35–65 with mild to moderate androgenetic alopecia. Participants are randomized to Active 1, Active 2, or Placebo and take one capsule daily for 84 days, with visits at baseline, day 42, and day 84. Hair growth, hair loss, brightness, and color lightness are measured using phototrichogram and spectrophotometer/colorimeter techniques, along with standard hair assessments. The study aims to determine whether the active supplements improve objective hair parameters and perceived hair quality compared with placebo.
Why it matters
Potential benefit: If successful, participants may experience improved hair growth and hair appearance.
How similar studies have gone: Previous studies with similar plant-based formulations have shown variable but sometimes positive effects on hair parameters; this study tests two formulations against placebo.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Healthy male subjects
2. Subjects of Caucasian ethnicity
3. Subjects aged between 35 and 65 years (extremes included)
4. Subjects with mild to moderate androgenetic alopecia, corresponding to the grade II to III vertex on Hamilton-Norwood scale
5. Subjects with hair that is at least 5-7 cm long
6. Subjects with visible grey or white hair
7. Subjects registered with national health service
8. Subjects certifying the truthfulness of the personal data disclosed to the Principal Investigator or designated personnel
9. Subjects able to understand the language used in the investigation center and the information given by the Principal Investigator or designated personnel
10. Subjects able to respect the instructions given by the Principal Investigator or designated personnel as well as able to respect the study constraints and specific requirements
11. Subjects who commit not to change their daily routine or lifestyle during the study\*
12. Subjects on stable pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) for at least one month without any changes expected or planned during the study
13. Subjects informed about the test procedures who have signed a consent form and privacy agreement
* Subjects are asked not to change their usual hair hygiene and styling products (such as shampoo, conditioner, hair gel, hairspray, etc.) throughout the study
Exclusion Criteria:
1. Subjects who do not meet the inclusion criteria
2. Subjects with any acute, chronic, or progressive disease or condition that may interfere with the study data or that the Principal Investigator considers dangerous to the subject or incompatible with the requirements of the study \*\*
3. Subjects participating or planning to participate in other clinical trials
4. Subjects who participated in a similar study without respecting an adequate washout period (at least one month)
5. Subjects that have food intolerances or food allergies to ingredients of the study product
6. Subjects under pharmacological treatments that are considered incompatible with the study requirement by the Principal Investigator \*\*\*
7. Subjects who are currently using food supplement(s) and/or products with the same activity as the study product, or who haven't observed an adequate washout period (at least one month)
8. Subjects admitted to a health or social facility
9. Subjects planning a hospitalization during the study
10. Subjects not able to be contacted in case of emergency
11. Subjects deprived of freedom by administrative or legal decision or under guardianship
12. Subjects who have or have had a history of alcohol or drug addiction
13. Subjects with eating disorders (i.e. bulimia, psychogenic eating disorders, etc.)
* Including oncological diseases, diabetes, autoimmune diseases, acute inflammatory diseases, ongoing infectious diseases, and alopecia areata.
* Including corticosteroid drugs, biological drugs, and cytostatic drugs.
Where it's running
-
Nutratech S.r.l. - Via Francesco Todaro 20/22
Rende, Cosenza, Italy Recruiting -
Complife Italia S.r.l. - Via Mortara 171
Ferrara, Ferrare, Italy Recruiting -
Complife Italia S.r.l. - Via Signorelli 159
Garbagnate Milanese, Milan, Italy Recruiting -
Complife Italia S.r.l. - Piazzale Siena 11
Milan, Milan, Italy Recruiting -
Complife Italia SRL - Corso San Maurizio 25
Biella, Pavia, Italy Recruiting -
Complife Italia S.r.l. - Via Monsignor Angelini 21
San Martino Siccomario, Pavia, Italy Recruiting
Study contacts
- Principal investigator: Enza Cestone, Dr — Complife Italia Srl
- Study coordinator: Jessica Lacetera
- Email: jessica.lacetera@complifegroup.com
- Phone: 0382 25504
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dual treatment with KeraFactor and Revian LED for female pattern hair loss
This study tests whether using a scalp-stimulating serum together with a Revian LED cap helps women with androgenic alopecia grow more hair than each treatment alone or placebo.
-
MF1: a first-in-human test in healthy men and people with Parkinson's disease
This early study tests MF1 to see if it is safe and how it behaves in the body, first in healthy Japanese men and then in people with Parkinson's disease- related symptoms.
-
Biphasic IVM for POSEIDON Group 1 in young women with poor response
This trial tests whether a two-step in vitro maturation process can help young women with normal ovarian reserve who retrieve too few eggs after standard stimulation.
-
JAK2 levels in balding and non-balding scalp before and after topical minoxidil
This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.
-
Collavant n2 for exercise-related knee discomfort in active men
This will see if taking 40 mg of Collavant® n2 daily helps reduce knee discomfort and improve joint function in healthy amateur male runners who get knee pain with exercise.
-
Olive oil extract for improving knee comfort and function
This will test whether taking an olive oil extract every day for six weeks helps reduce knee pain and improve knee function in adults 40–75 who have ongoing knee discomfort.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.